Assessment of etidronic acid plus alfacalcidol for the treatment of osteopenia in steroid-dependent asthmatics: A pilot study of five cases

Hirofumi Tsugeno, Mutsuo Nakai, Makoto Okamoto, Tadashi Yokoi, Shingo Takata, Norikazu Nishida, Kozo Ashida, Fumihiro Mitsunobu, Haruo Yuki, Yoshiro Tanizaki, Yasushi Shiratori

Research output: Contribution to journalArticle

Abstract

Objective: Osteoporosis is generally known to be one of the most serious adverse effects of long-term corticosteroid administration. Recently it was discovered that corticosteroid-induced osteoporosis occurs not only in trabecular bone but also in cortical bone, leading to a reduction in cortical bone strength. To ameliorate corticosteroid-induced bone injury, we administered etidronic acid plus alfacalcidol to five steroid-dependent asthmatics for 4 years and monitored therapeutic responses in trabecular bone and cortical bone using peripheral quantitative computed tomography (pQCT). Patients and interventions: The five steroid-dependent asthmatic patients included two males and three females, with a mean age 68.2 years, taking a mean daily dose of oral prednisolone of 7 mg/day. Etidronic acid 200 mg/day was administered for 14 consecutive days every 4 months for 4 years, while alfacalcidol 0.5μg was administered daily for 4 years. Main outcome measures and results: Every 4 months, the number of vertebral fractures was assessed by lateral vertebral radiographs, and the total radial bone mineral density (BMD), trabecular BMD, cortical BMD, Relative Cortical Volume (RCV) and Strength Strain Index (SSI) were assessed by pQCT (Stratec XCT-960). At follow-up, no new fractures had occurred, the trabecular BMD was found to be slightly increased (from 117.2 mg/cm3 at baseline to 121.6 mg/cm3 after 48 months), and no significant decreases were observed in the total BMD, cortical BMD, RCV or SSI. Conclusion: Based on these findings, etidronic acid plus alfacalcidol seems to be effective in preventing steroid-induced bone injury, not only in terms of trabecular and cortical BMD, but also in terms of cortical bone volume and strength, which may lead to a decrease in non-vertebral fractures. However, further investigation is required with a larger sample size and a longer administration period to confirm these findings.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalClinical Drug Investigation
Volume23
Issue number2
DOIs
Publication statusPublished - 2003

Fingerprint

Etidronic Acid
Metabolic Bone Diseases
Bone Density
Steroids
Adrenal Cortex Hormones
Bone and Bones
Therapeutics
Osteoporosis
Tomography
Wounds and Injuries
Prednisolone
Cortical Bone
alfacalcidol
Sample Size
Outcome Assessment (Health Care)
Cancellous Bone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Assessment of etidronic acid plus alfacalcidol for the treatment of osteopenia in steroid-dependent asthmatics : A pilot study of five cases. / Tsugeno, Hirofumi; Nakai, Mutsuo; Okamoto, Makoto; Yokoi, Tadashi; Takata, Shingo; Nishida, Norikazu; Ashida, Kozo; Mitsunobu, Fumihiro; Yuki, Haruo; Tanizaki, Yoshiro; Shiratori, Yasushi.

In: Clinical Drug Investigation, Vol. 23, No. 2, 2003, p. 99-105.

Research output: Contribution to journalArticle

Tsugeno, Hirofumi ; Nakai, Mutsuo ; Okamoto, Makoto ; Yokoi, Tadashi ; Takata, Shingo ; Nishida, Norikazu ; Ashida, Kozo ; Mitsunobu, Fumihiro ; Yuki, Haruo ; Tanizaki, Yoshiro ; Shiratori, Yasushi. / Assessment of etidronic acid plus alfacalcidol for the treatment of osteopenia in steroid-dependent asthmatics : A pilot study of five cases. In: Clinical Drug Investigation. 2003 ; Vol. 23, No. 2. pp. 99-105.
@article{3342fa66e7454f6ba0892f21986d535c,
title = "Assessment of etidronic acid plus alfacalcidol for the treatment of osteopenia in steroid-dependent asthmatics: A pilot study of five cases",
abstract = "Objective: Osteoporosis is generally known to be one of the most serious adverse effects of long-term corticosteroid administration. Recently it was discovered that corticosteroid-induced osteoporosis occurs not only in trabecular bone but also in cortical bone, leading to a reduction in cortical bone strength. To ameliorate corticosteroid-induced bone injury, we administered etidronic acid plus alfacalcidol to five steroid-dependent asthmatics for 4 years and monitored therapeutic responses in trabecular bone and cortical bone using peripheral quantitative computed tomography (pQCT). Patients and interventions: The five steroid-dependent asthmatic patients included two males and three females, with a mean age 68.2 years, taking a mean daily dose of oral prednisolone of 7 mg/day. Etidronic acid 200 mg/day was administered for 14 consecutive days every 4 months for 4 years, while alfacalcidol 0.5μg was administered daily for 4 years. Main outcome measures and results: Every 4 months, the number of vertebral fractures was assessed by lateral vertebral radiographs, and the total radial bone mineral density (BMD), trabecular BMD, cortical BMD, Relative Cortical Volume (RCV) and Strength Strain Index (SSI) were assessed by pQCT (Stratec XCT-960). At follow-up, no new fractures had occurred, the trabecular BMD was found to be slightly increased (from 117.2 mg/cm3 at baseline to 121.6 mg/cm3 after 48 months), and no significant decreases were observed in the total BMD, cortical BMD, RCV or SSI. Conclusion: Based on these findings, etidronic acid plus alfacalcidol seems to be effective in preventing steroid-induced bone injury, not only in terms of trabecular and cortical BMD, but also in terms of cortical bone volume and strength, which may lead to a decrease in non-vertebral fractures. However, further investigation is required with a larger sample size and a longer administration period to confirm these findings.",
author = "Hirofumi Tsugeno and Mutsuo Nakai and Makoto Okamoto and Tadashi Yokoi and Shingo Takata and Norikazu Nishida and Kozo Ashida and Fumihiro Mitsunobu and Haruo Yuki and Yoshiro Tanizaki and Yasushi Shiratori",
year = "2003",
doi = "10.2165/00044011-200323020-00003",
language = "English",
volume = "23",
pages = "99--105",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Assessment of etidronic acid plus alfacalcidol for the treatment of osteopenia in steroid-dependent asthmatics

T2 - A pilot study of five cases

AU - Tsugeno, Hirofumi

AU - Nakai, Mutsuo

AU - Okamoto, Makoto

AU - Yokoi, Tadashi

AU - Takata, Shingo

AU - Nishida, Norikazu

AU - Ashida, Kozo

AU - Mitsunobu, Fumihiro

AU - Yuki, Haruo

AU - Tanizaki, Yoshiro

AU - Shiratori, Yasushi

PY - 2003

Y1 - 2003

N2 - Objective: Osteoporosis is generally known to be one of the most serious adverse effects of long-term corticosteroid administration. Recently it was discovered that corticosteroid-induced osteoporosis occurs not only in trabecular bone but also in cortical bone, leading to a reduction in cortical bone strength. To ameliorate corticosteroid-induced bone injury, we administered etidronic acid plus alfacalcidol to five steroid-dependent asthmatics for 4 years and monitored therapeutic responses in trabecular bone and cortical bone using peripheral quantitative computed tomography (pQCT). Patients and interventions: The five steroid-dependent asthmatic patients included two males and three females, with a mean age 68.2 years, taking a mean daily dose of oral prednisolone of 7 mg/day. Etidronic acid 200 mg/day was administered for 14 consecutive days every 4 months for 4 years, while alfacalcidol 0.5μg was administered daily for 4 years. Main outcome measures and results: Every 4 months, the number of vertebral fractures was assessed by lateral vertebral radiographs, and the total radial bone mineral density (BMD), trabecular BMD, cortical BMD, Relative Cortical Volume (RCV) and Strength Strain Index (SSI) were assessed by pQCT (Stratec XCT-960). At follow-up, no new fractures had occurred, the trabecular BMD was found to be slightly increased (from 117.2 mg/cm3 at baseline to 121.6 mg/cm3 after 48 months), and no significant decreases were observed in the total BMD, cortical BMD, RCV or SSI. Conclusion: Based on these findings, etidronic acid plus alfacalcidol seems to be effective in preventing steroid-induced bone injury, not only in terms of trabecular and cortical BMD, but also in terms of cortical bone volume and strength, which may lead to a decrease in non-vertebral fractures. However, further investigation is required with a larger sample size and a longer administration period to confirm these findings.

AB - Objective: Osteoporosis is generally known to be one of the most serious adverse effects of long-term corticosteroid administration. Recently it was discovered that corticosteroid-induced osteoporosis occurs not only in trabecular bone but also in cortical bone, leading to a reduction in cortical bone strength. To ameliorate corticosteroid-induced bone injury, we administered etidronic acid plus alfacalcidol to five steroid-dependent asthmatics for 4 years and monitored therapeutic responses in trabecular bone and cortical bone using peripheral quantitative computed tomography (pQCT). Patients and interventions: The five steroid-dependent asthmatic patients included two males and three females, with a mean age 68.2 years, taking a mean daily dose of oral prednisolone of 7 mg/day. Etidronic acid 200 mg/day was administered for 14 consecutive days every 4 months for 4 years, while alfacalcidol 0.5μg was administered daily for 4 years. Main outcome measures and results: Every 4 months, the number of vertebral fractures was assessed by lateral vertebral radiographs, and the total radial bone mineral density (BMD), trabecular BMD, cortical BMD, Relative Cortical Volume (RCV) and Strength Strain Index (SSI) were assessed by pQCT (Stratec XCT-960). At follow-up, no new fractures had occurred, the trabecular BMD was found to be slightly increased (from 117.2 mg/cm3 at baseline to 121.6 mg/cm3 after 48 months), and no significant decreases were observed in the total BMD, cortical BMD, RCV or SSI. Conclusion: Based on these findings, etidronic acid plus alfacalcidol seems to be effective in preventing steroid-induced bone injury, not only in terms of trabecular and cortical BMD, but also in terms of cortical bone volume and strength, which may lead to a decrease in non-vertebral fractures. However, further investigation is required with a larger sample size and a longer administration period to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=0037218447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037218447&partnerID=8YFLogxK

U2 - 10.2165/00044011-200323020-00003

DO - 10.2165/00044011-200323020-00003

M3 - Article

AN - SCOPUS:0037218447

VL - 23

SP - 99

EP - 105

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 2

ER -